Sports performance research ↗ · Military & occupational performance ↗
← Archival researchAUTHOR AND CITATION SEARCH / 6 NOVEMBER 2026Beyond the Shustov thesis.
Original papers, related research and the missing documents that could explain the older fatigue findings.
This map follows Evgeny Borisovich Shustov (Евгений Борисович Шустов, Е. Б. Шустов) through coauthors and references. The map includes historical sources newly traced for Molekul and a 2026 human physiology report. Publication dates and newly discovered records are distinguished. Author initials matter: a shared surname, citation or institution does not establish collaboration.
Following the same authors into longer-term outcomes
The 2024 Shustov–Melnikova–Potapov methods paper compares follow-up measurements. It is cited by the 2026 Potapov–Shustov rat study, which includes a model-dependent favorable response and an unfavorable inositol-derivative finding.
These papers extend the author and endpoint trail. Shared methods do not establish independent replication, and the aminoethanol preparation has not been equated with ADK-17 or FDES.
Polyprenols, marine extracts and a registered human trial
The Melnikova–Shustov citation trail now connects animal cytoprotection work, an analytical conference and related Russian human research on a different preparation. The new Polyprenols / Ropren collection ↗ keeps the plant preparations together while distinguishing their sources. Brown-algae extracts and sea-urchin gonad material remain separate mixtures.
POLYNCOR: one human program, several reports
The original trial record, NCT03122340 ↗, describes a Russian randomized, placebo-controlled adjunctive Ropren study in acute coronary syndrome. It lists 70 actual enrollees and completed status. Registration was first posted in April 2017, after the listed November 2015 start. No tabular results are posted in the retrieved registry record.
| Source | What is available | Open question |
|---|---|---|
| Registry | 70 actual enrollees; several biochemical and cognitive outcomes. | Recover the participant flow and full results. |
| 2018 clinical paper ↗ | Abstract reports lower cholesterol/ALT and fewer statin adjustments. | The analyzed denominator and complete safety accounting are missing from the abstract. |
| 2021 conference report ↗ | 68 participants, 34 per arm; within-arm cognition and mood changes. | Reconcile 70 versus 68; later placebo scores are absent. |
The 2021 report’s within-arm MoCA improvement is not a placebo-adjusted estimate. Shustov is not an author of either clinical report; the connection is the related polyprenol literature. These reports do not establish general cognitive enhancement or a class-wide benefit.
A myelin finding, with a more limited interpretation
Khodanovich and colleagues’ 2019 original paper ↗ is recovered as complete open-access XML. Twenty-seven mice were allocated to three groups; histology used seven per group. The methods describe random allocation, blinded tissue analysis and adjustment for multiple comparisons. Treated animals had more myelin-marker signal than toxin-exposed vehicle controls.
The authors explicitly leave open whether this reflects protection against continuing injury or enhanced repair. This toxin-induced model does not establish restored immune tolerance, isolated remyelination or clinical efficacy in multiple sclerosis. Shustov is not an author.
Three direct Shustov branches and an unfavorable result
Polyprenols and oxidative injury ↗
A neuropharmacology report describes antioxidant-enzyme changes. Its English abstract says “polyphenols” in one sentence; preparation identity needs the original paper.
Siberian-fir polyprenols ↗
The previously queued source now has a qualitative extraction. The complete PDF and numerical appraisal remain missing. Its preparation is not assumed equivalent to Ropren.
Green-sea-urchin gonad lyophilisate ↗
A related rat study describes partial compensation under adverse exposures. This is an animal-derived mixture, not a polyprenol or purified peptide.
A boundary on the protective claim: the 2021 brown-algae paper ↗ reports different osmotic/peroxide resistance effects for Fucus vesiculosus and Saccharina latissima. It also reports that higher or longer exposure reduced red-cell membrane resistance. A favorable selected combination does not establish synergy or justify assuming that greater exposure is better.
The conference and institutional route
Two 2022 Environmental Control Systems leads are now distinct: an analytical polyprenol-measurement contribution involving a mixed formulation, and a combined-exposure model abstract on p.132. The full proceedings remain unrecovered. An assay used to characterize a mixture is not a clinical test of that mixture.
The Golikov center’s 2023 institutional publication list ↗ corroborates the p.132 citation and identifies A. V. Belskaya’s historical drug-toxicology laboratory affiliation. Follow Melnikova, Belskaya, Kubarskaya, Bondarenko, Podolskaya and Krasnov through the cited papers for the preparation and analytical records. This is an archival route; no current employment or access is assumed.
The Tomsk route: the registry identifies E. V. Vyshlov as principal investigator; the clinical reports also name E. I. Tsoi/Tsoy and V. V. Ryabov. The myelin paper leads to M. Y. Khodanovich and V. L. Yarnykh. V. B. Trusov appears in both the 2018 clinical and 2019 animal author lists; verify identity and program roles before treating the teams as independent. These are publication-based retrieval leads, and no researcher has been contacted.
Next documents: POLYNCOR’s flow diagram and complete clinical reports; the original 2022 p.132 and analytical poster; and the full algae, fir-polyprenol and sea-urchin tables. Compare preparations and cohort dates before counting replication.
All source records and access limits ↓ · Open the polyprenol collection ↗
The nutrition branch: human leads and reused animal results
The complete 2017 Karkishchenko–Novikov–Shustov report and 2022 Gunina–Shustov paper are now recovered. Comparing them reveals a small human study worth tracing, earlier product testing, and animal results that must be reconciled before counting independent evidence.
2017 original publisher PDF ↗ · 2022 original PDF in the university repository ↗
A 21-man study and a named institutional lead
Printed page 22 of the 2017 report describes a MioAktiv study in 21 male skiing-sport athletes, mean age 23.1 ± 1.5 years. The authors call it randomized and placebo-controlled and attribute its conduct to the experimental sports-medicine department of the Burnazyan Federal Medical Biophysical Center, headed in that account by S. M. Razinkin. That is a historical institutional attribution; it does not establish his personal role in every experiment or current employment.
Figure 3 reports the following group averages after the product course. These are percentages of each group’s baseline, with baseline equal to 100. Arm sizes, raw values, confidence intervals, allocation procedures and endpoint-specific between-group tests are not supplied in this account.
| Outcome | Control | MioAktiv |
|---|---|---|
| Total time to exercise limit | 102 | 105 |
| Time at critical power | 153 | 193 |
| Work performed | 96 | 105 |
| Power | 94 | 100 |
| Maximum oxygen consumption | 96 | 99 |
The control group also improved substantially on time at critical power. Maximum oxygen consumption remained below baseline in both plotted groups, despite the text describing an increase. The figure does not establish a treatment-specific improvement in oxygen consumption. Recover the center’s original protocol and report before calculating an effect size.
Why the 2022 paper is not another independent confirmation
The later methods explicitly state 127 athletes: 102 participants across swimming, running and skiing, plus 25 placebo controls. The reported 18.7–21.4% human speed increases come without raw distance times, sport-specific control results or a clearly defined statistical contrast. A separate martial-arts self-assessment is described without a participant count. Its relationship to the stated 127 is unclear.
The 2017 report also describes product appraisal during 2012–2013 in more than 100 athletes. This is a lead to possible shared reporting, not proof that all later human participants were the same people. The 21-man study, wider appraisal and 127-person report must not be added together as a verified unique cohort.
| Finding | 2017 report | 2022 paper | Interpretation |
|---|---|---|---|
| Pre-Fuse rat work index at testing | Control 229 ± 13; product 292 ± 24 | The same values | Matching Table 1 values, not evidence of a new independent experiment. |
| Uncertainty label in Table 1 | Mean ± standard error | Mean ± standard deviation | No explanation of a recalculation. Keep uncertainty type unresolved when comparing these numbers. |
| Pre-Fuse mini-pig running time | 24.0 ± 2.5 to 39.4 ± 5.7 minutes; p=0.04 | The same values and p-value | The reported 64% change is an animal result. |
| MioAktiv animal figure and Pre-Fuse behavior table | Figure 1 and Table 2 | Matching plotted and tabulated values | Trace the source experiments rather than count publication dates as replications. |
Both preparations contain multiple ingredients. These reports cannot isolate a benefit of succinate, carnosine or any other single constituent. The 2022 paper names university research programs in its funding statement and declares no conflict of interest; its broad safety conclusion is not supported by a detailed adverse-event accounting.
Another original recovered: 30 taekwondo athletes
The 2022 references lead to Shustov, Novikov, Berzin, Kim and Bolotova’s Functional sports nutrition for martial athletes: development and efficacy criteria, Biomeditsina, 2017(1):10–23. The complete original PDF is recovered. It describes the Ataka three-module nutrition program in 30 athletes aged 17–26 at St. Petersburg’s Kometa club, with I. Pak named as head coach in the historical methods.
The authors report random allocation: 20 participants received the program and ten the control nutrition mixture during 28 days of training. General endurance is tabulated as 122.5 ± 2.5 points in the active group versus 114.3 ± 2.6 in controls at day 28, with a single baseline column of 112.5 ± 2.8. The active result’s ** denotes p<0.01 versus baseline. It is not a marked comparison with control. Sex distribution and training schedules also differed, and no allocation-concealment or blinding procedure is described.
Read the original human tables and limitations ↗. This is the whole base/pre-training/relaxation program, so its findings cannot be attributed to Pre-Fuse alone or one ingredient. Its participant relationship to the other nutrition papers remains unresolved.
The Titovich trail reaches a corrected 2018 method paper
Razygraev, Yushina and Titovich’s FDES enzyme paper has a publisher correction ↗. The author-uploaded corrected text ↗ reports an exploratory brain glutathione-peroxidase signal under hypoxia without adjustment for multiple comparisons. It is one experiment, not two. Shustov is not an author.
Its reference 3 connects FDES to patent RU2588365C1 ↗, published in 2016, with Okovityi, Shustov, Bolotova and Titovich listed as inventors. This strengthens the candidate’s provenance; the enzyme finding and patent do not establish human neuroprotection.
A precise spaceflight acquisition target
N. N. Karkishchenko and E. B. Shustov’s contribution on pharmacological support during flight emergencies and landing is cited on pages 406–407 of the XI Manned Space Flights conference, 10–12 November 2015. The 2017 publisher reference list ↗ supplies the citation; the Gagarin training center’s publication list, item 482 ↗ catalogs the 2015 volume as 574 pages. The original two-page contribution is still missing, so no drug-use or flight-trial result is inferred.
Next retrieval priorities: the Burnazyan center’s 21-athlete protocol and report; the original 2012–2013 appraisal and its relation to the 2022 cohorts; and the 2015 proceedings’ pp.406–407 with title and contents pages.
Source records and access limits ↓ · FDES / ADK-17 collection ↗
The next branch: coded candidates and human physiology
The public author record ORCID 0000-0001-5895-688X ↗, publisher references and recovered proceedings lead to these additional reports. ORCID was used for discovery; authorship and findings were checked against publication records.
| Candidate | Identity supported by the reviewed sources | What it adds |
|---|---|---|
| FDES / ФДЭС / PDES | Succinic salt of a diethylaminoethanol fumaric ester. | Performance screening, experimental neuroprotection and animal cognition. |
| ADK-17 / АДК-17 | A dimethylaminoethanol derivative involving butanedioic and trans-butenedioic acids. Confirm exact preparation specifications across reports. | Preclinical safety and rabbit pharmacokinetics. The shared ADK letters do not identify it as an adamantane. |
| Ethylthiobenzimidazole fumarate | A Bemitil-related salt, structurally separate from the aminoethanol candidates. | The existing stress and formulation branch; its findings are not transferred to FDES or ADK-17. |
Open the single FDES / ADK-17 research collection ↗
ADK-17 safety ↗
A Shustov–Kim animal safety report covers immune and reproductive-developmental endpoints. The negative findings apply to the assessed conditions.
ADK-17 pharmacokinetics ↗
The rabbit report gives a 60–90 minute plasma peak and a 4.3-hour elimination half-life. Trace detection for longer periods is a different measurement.
A later environmental-stress comparison ↗
A 2023 issue article appeared online in February 2024. Its English abstract mixes dimethyl and diethyl naming, so preparation identity must be resolved before pooling.
FDES and experimental cerebral ischemia ↗
Bolotova, Titovich and Shustov reported favorable functional and tissue measures in male rats. Full methods and denominators remain to be retrieved.
FDES cognition: original tables recovered ↗
The five-page journal PDF supplies memory-task results and reveals conflicting group sizes, percentages and administration descriptions.
Two human studies that extend the physiology
2026: orthostatic instability in 145 apparently healthy men aged 18–25 ↗. Kim, Shustov, Zaitseva, Zaytsev and Lemeshchenko examined active standing responses alongside autonomic and laboratory measures. This is a current human physiology link to asthenia and maladaptation, without a drug-treatment comparison. It is not a diagnosed POTS cohort.
2022: physical activity and immune measures in 77 young men ↗. The activity groups had different patterns of immune measures; most stayed within reference ranges. This supports studying the relationship between workload and immune regulation, without establishing autoimmune-treatment efficacy. Russian and English versions count as one report.
The conference and archival trail is now more specific
- 5–7 October 2023, Peptides, Hormones and the Nervous System, pp.76–77: Kim’s pharmacokinetics account is recovered from a university-hosted proceedings PDF. Its matching chemistry and rabbit values suggest overlap with the later ADK-17 paper.
- 20–24 November 2023, VI Russian Pharmacology Congress: the publisher supplement lists ethanolamine performance screening on p.72, a Cytoflavin comparison on p.36a, and a related Cytoflavin–Trekrezan mountaineer report on p.37. All three one-page publisher PDFs have now been recovered and visually checked. Shustov is absent from the mountaineer report’s author list.
- 2017, Novikov–Shustov post-flight maladaptation review: the original publisher overview is recovered. Reference 7 identifies Karkishchenko–Shustov’s contribution at the XI Manned Space Flights conference, 10–12 November 2015, pp.406–407. The complete contribution and the 2017 printed article remain missing.
A small human comparison with a neutral physical endpoint
The mountaineer abstract ↗ includes 15 men: seven received placebo and eight the sequential Trekrezan/Cytoflavin preparations. Both groups trained. Oxygen consumption improved by 5% and 7% within the respective groups, but the between-group difference was not significant. An attention improvement was reported with p=0.028; the exact contrast and raw scores are unclear. This does not establish combination synergy.
The 2017 and 2022 MioAktiv / Pre-Fuse originals are now recovered and compared below ↓. Their overlapping animal results are flagged. Shustov’s 2024 Siberian-fir polyprenol paper now has an abstract-level extraction in the natural-product branch ↑; complete numerical appraisal remains pending.
The first six branches
FDES and aminoethanol derivatives
The Bolotova–Shustov–Okovityi paper extends the aminoethanol program described in chapter 6.4 of the recovered book. Cohort overlap remains unresolved.
Read the source appraisal ↗Cortexin, Semax and Dalargin: a direct Shustov paper
A direct link between Shustov’s work and peptide-profile research. Matching mass-profile and outcome tables are now confirmed in book section 6.7. The expanded review includes PPK-V, doses, raw times and a neutral 5–10 kDa swimming association; these reports are not independent replication.
Read the source appraisal ↗Bemitil fumarate under combined stress
Bolotova, Bolotina and Shustov investigated the fumarate salt under combined hypoxic and thermal stress. The indexed abstract reports improved performance. Full numerical appraisal remains open.
Open the original publication ↗Ornithine, ammonia handling and recovery
A separate recovery hypothesis involving ammonia metabolism and L-ornithine-L-aspartate. The review leads to earlier exercise studies; it does not itself add a clinical trial.
Read the publisher review ↗Succinate as a signal: SUCNR1
A mechanistic branch beyond energy substrates. Receptor signaling is a research rationale; it does not establish the mechanism of every succinate-containing preparation.
Open the publisher record ↗A later fumarate formulation program
Kasymov, Marchenko and Basevich studied matrix tablets of ethylthiobenzimidazole fumarate. Shustov is not a coauthor. The reported 12-hour release concerns laboratory dissolution, not demonstrated clinical duration.
Open the publisher record ↗The book contains more than Pirabel
Работоспособность. Утомление. Коррекция (Okovityi, Shustov and Bolotova; Knorus, 2019; ISBN 978-5-406-07773-3) is already recovered as a 330-page document. The contents, selected narrative passages and bibliography were checked further for this update. This is a targeted reading, not an appraisal of every experiment.
| Pages | Research lead | What still needs checking |
|---|---|---|
| 184–189 | Pirabel and prolonged physical work ↗ | The already catalogued 78-volunteer report needs comparison with the 1994 and 1996 originals. |
| 210–250 | Aminoethanol derivatives, including SDMAF and FDES | Distinct candidates and salts; compare the original experiments with the later 2020 paper. |
| 272–291 | Bemitil salts and etomerzol salts | Keep the maleate, fumarate and hydrochloride preparations separate when comparing outcomes. |
| 292–302 | Neuroprotective peptides and experimental brain-peptide complexes | Compare with the 2020 mass-profile paper before counting independent evidence. |
A less favorable result: Table 106 on printed page 289 reports grip strength of 36.0 ± 2.1 N with ethylthiobenzimidazole fumarate plus training, versus 43.4 ± 1.1 N with training alone (10 mice per group; reported p=0.02). The treated group performed worse than trained controls, despite exceeding the initial reference level. This endpoint should accompany the book’s favorable endurance discussion.
The book identifies etomerzol as 5-ethoxy-2-ethylthiobenzimidazole hydrochloride. It explicitly pairs “etomerzol (tomerzol)” on printed page 266. This resolves the naming connection in this source, without establishing equivalence across every historical preparation.
Open the public author-upload record ↗The highest-value documents to find
The first three citations are visible on printed pages 320–321 of the recovered book. Their original documents remain missing. These are acquisition targets, not additional clinical-study records.
- 1996 Maritime Medical Journal, issue 6, pages 4–7. E. B. Shustov and A. A. Ikhalainen, Повышение работоспособности в условиях физического утомления. Obtain all four pages to resolve the population, allocation, comparisons and relationship to the thesis.
- 1994 conference proceedings, page 17. Shustov, Aksenov, Bakhtin and Ikhalainen, Bemitil and etomerzol during prolonged physical workload, in Антигипоксанты и актопротекторы: итоги и перспективы, St. Petersburg. Obtain the abstract plus the contents and title pages.
- The complete 1996 doctoral dissertation. The current web transcription is an author abstract. The book cites a 443-page dissertation, while other trails disagree on length. Authenticate the library record and title page before assigning a page count or reusing its cohorts.
- 1998 two-part extreme-exposure publication. Shustov and Ikhalainen, РЖ «Экология человека», separate series 86: issue 3, pages 1–33; issue 4, pages 1–48. Confirm whether these are reviews, reports or original investigations.
- The original 2018 peptide paper. Пептидная биорегуляция резистентности к экстремальным воздействиям, Биомедицина (2):4–14. An existing library lead now connects to the later 2020 paper and Kim’s 2023 review; the original PDF still needs retrieval.
- 2017 FMBA methodological guidance. MR21-44-2017, 98 pages, concerns preclinical antihypoxic activity; MR21.43, 133 pages, concerns physical performance. These are methods documents, not peptide efficacy monographs or trials.
Check the book’s cited-source trail ↗ · Existing dissertation acquisition record ↗
Follow the coauthors
The recovered nutrition papers add L. M. Gunina, I. F. Belenichev, N. L. Vysochina, R. V. Golovashchenko and O. V. Morozova to the citation search. Their 2017 predecessor names the Burnazyan center’s sports-medicine department and its then head S. M. Razinkin; that is an institutional retrieval lead, not an assertion of authorship. Additional coauthors include I. A. Titovich for the FDES animal work, and I. P. Zaitseva, O. N. Zaytsev and A. V. Lemeshchenko for the human physiology branch. These are publication-based search trails. Affiliations belong to the cited publications and are not assertions of current employment. No researcher has been contacted.
| Coauthors | Connection to follow | Source anchor |
|---|---|---|
| S. V. Okovityi / V. Ts. Bolotova | Fatigue, aminoethanol derivatives, Bemitil salts; Saint Petersburg State Chemical and Pharmaceutical University. | 2020 screening paper ↗; 2019 book. |
| D. Yu. Ivkin / A. S. Ivkina / A. E. Kim / S. L. Lublin / M. S. Nesterov | Peptide profiles and experimental complexes across university, academy and FMBA affiliations. | 2020 peptide paper ↗. Kim’s 2023 review is a related citation trail. |
| A. A. Ikhalainen / I. V. Aksenov / M. Yu. Bakhtin | Earlier prolonged-workload experiments and the missing conference/journal originals. | Book references 180–182; archival targets above. |
| N. N. / V. N. Karkishchenko | Preclinical methods, interpretation and extrapolation of performance measures. | References 7, 9 and 10 of the 2020 peptide paper. |
| S. V. Radko | Succinate signaling and ornithine-related references. Verify each paper’s author list. | 2015 SUCNR1 review; references in the 2020 ornithine review. |
Access and attribution
Publisher HTML was checked for the two 2020 experimental papers and the ornithine review. Other access limits are recorded below. A review, a later formulation paper and a book retelling do not add independent clinical trials.
POLYNCOR trial registration — one program, multiple publication reports
Tomsk National Research Medical Center; principal investigator E. V. Vyshlov · 2017 · ClinicalTrials.gov NCT03122340; first posted 20 April 2017; latest listed update 26 April 2018
Original ClinicalTrials.gov API v2 JSON checked on 6 November 2026. Completed; 70 actual enrollees listed. Study began 1 November 2015, before first registration posting. Registry describes randomized parallel assignment, four masked roles and Phase III; phase is a registry label, not proof of approval or efficacy. No tabular results were posted in the retrieved record. The 2018 paper is linked; the 2021 abstract reports 68 participants. Recover the flow diagram and reconcile outcomes across reports.
Open the source trail ↗Determination of polyprenols using the Milichrom A-02 — analytical conference trail
Ya. K. Kalninya and colleagues; E. B. Shustov listed · 2022 · Environmental Control Systems — 2022; original proceedings and poster section 03
Indexed original poster/proceedings passages checked; complete proceedings download failed. Analytical work on a mixture involving Saccharina latissima extract, green-sea-urchin gonad material and Prenolit. Detection/standardization is not efficacy testing. Retrieve the original page to verify full author spelling, preparation specification and validation; do not infer that the mixture itself has proven clinical activity.
Open the source trail ↗ · Publisher-listed PDF ↗Combined low-level chemical and electromagnetic exposure model — conference acquisition target
M. V. Melnikova; E. B. Shustov; A. V. Belskaya; A. A. Bondarenko; M. E. Shemaev; A. S. Melekhova; A. A. Vataeva; K. V. Masterova · 2022 · Environmental Control Systems — 2022, Sevastopol, p.132
Citation corroborated in the Golikov center’s 2023 institutional publication list; original p.132 not recovered. Specific acquisition target behind the combined-exposure program. The later polyprenol and sea-urchin reports use related model descriptions, but common design and coauthors do not establish cohort identity or replication.
Open the source trail ↗ · Publisher-listed PDF ↗Golikov center: young scientists’ council and publication lists, 2023
Golikov Research Clinical Center of Toxicology, FMBA Russia · 2023 · Institutional eight-page roster and publication list
Original institutional PDF text checked through web retrieval; selected publication/affiliation passages reviewed. Dated institutional evidence for A. V. Belskaya and the shared algae/model publication trail. Describes Belskaya in the drug-toxicology laboratory in 2023. This supports archival routing, not current employment, access to participants or a new research result. No researcher contacted.
Open the source trail ↗ · Publisher-listed PDF ↗Fundamentals of human vital activity under extreme conditions: adaptation, deadaptation, correction
V. S. Novikov; E. B. Shustov · 2021 · Vestnik obrazovaniya i razvitiya nauki RAEN. 25(3):5–13. DOI 10.26163/RAEN.2021.53.71.001
Indexed original title/abstract and citation checked; listed PDF redirected to the publisher homepage. Conceptual bridge between adaptation and modular functional nutrition. Not a new controlled trial. Original complete text and its historical citations remain retrieval targets.
Open the source trail ↗FDES cognition paper — recovered original journal PDF
V. Ts. Bolotova; I. A. Titovich; E. B. Shustov · 2022 · Journal Biomed. 18(3):104–108; source version of shustov-fdes-cognition-2022
All five pages read; methods and both tables visually checked. A copy of the same publication, not another experiment. Retains the n=15 / 40-rat conflict, incompatible percentages and inconsistent administration timing.
Open the source trail ↗ · Publisher-listed PDF ↗Oral pharmacokinetics of the fumarate salt of a DMAE succinate ester — conference account
A. E. Kim · 2023 · Peptides, Hormones and the Nervous System. International conference, St. Petersburg, 5–7 October 2023; pp.76–77
University-hosted original proceedings recovered; pp.76–77 read, conclusions visually checked. Chemical description and rabbit PK values match the later Kim–Shustov ADK-17 article. Treat as potentially overlapping reporting, not replication. Full journal tables and raw PK data remain priorities.
Open the source trail ↗ · Publisher-listed PDF ↗Performance-stimulator screening among ethanolamine, butanedioic and trans-butenedioic-acid derivatives
A. E. Kim; V. P. Ganapolsky; E. B. Shustov; V. Ts. Bolotova · 2023 · Experimental and Clinical Pharmacology. 86(11s):72. DOI 10.30906/ekf-2023-86s-72. VI Russian Pharmacology Congress, 20–24 November 2023
Complete original publisher PDF recovered, read and visually checked. Screens twenty aminoethanol derivatives and reports performance signals for selected salts. Candidate selection and overlap with journal programs need reconciliation; no human efficacy demonstrated.
Open the source trail ↗ · Publisher-listed PDF ↗Antihypoxic activity of ethanolamine derivatives compared with Cytoflavin
V. P. Ganapolsky; A. E. Kim; V. O. Matytsin; E. B. Shustov · 2023 · Experimental and Clinical Pharmacology. 86(11s):36a. DOI 10.30906/ekf-2023-86s-36a; PDF printed page 36
Original publisher PDF read and visually checked; official poster listing matched. Poster C.1.1.10. Rat comparison with eight animals per active group and fifteen controls. Authors emphasize substantial individual variability; no human or clinically equivalent effect follows from the comparison.
Open the source trail ↗ · Publisher-listed PDF ↗Cytoflavin plus Trekrezan and mountaineer psychomotor function
V. P. Ganapolsky; V. O. Matytsin; A. E. Kim · 2023 · Experimental and Clinical Pharmacology. 86(11s):37. DOI 10.30906/ekf-2023-86s-37; same report as shustov-network-mountaineers-2023-study
Complete original publisher PDF read and visually checked. Fifteen men: seven placebo and eight in the sequential Trekrezan/Cytoflavin group. Both groups trained. Oxygen-consumption changes did not differ significantly between groups; attention contrast is incompletely specified. Shustov is not a coauthor; this is a source version, not another study or B-300.
Open the source trail ↗ · Publisher-listed PDF ↗Physiological patterns of acute post-flight maladaptation in cosmonauts
V. S. Novikov; E. B. Shustov · 2017 · Vestnik obrazovaniya i razvitiya nauki RAEN. (4):5–18
Original publisher overview and references checked; complete printed article not recovered. Links orthostatic deconditioning and post-flight asthenia to the older research program. Thymogen is a keyword, not proof of an in-flight drug trial. Reference 7 identifies Karkishchenko–Shustov, XI Manned Space Flights conference, 10–12 November 2015, pp.406–407. The publisher-listed article PDF redirected to its homepage when checked on 6 November 2026; no complete PDF recovery is claimed.
Open the source trail ↗Battery of tests for studying adaptogenic effects in preclinical trials
E. B. Shustov; S. V. Okovityi; V. Ts. Bolotova; A. E. Kim · 2021 · Pharmacy Formulas. 3(2):10–25. DOI 10.17816/phf65230
Publisher methodology text and abstract checked. Methodology and classification framework, not an independent treatment trial. Distinguishes adaptation and recovery measures from immediate performance stimulation.
Open the source trail ↗Pathophysiological interaction of hypoxia and physical load
A. E. Kim; E. B. Shustov; V. P. Ganapolsky; I. P. Zaitseva; A. V. Lemeshchenko · 2022 · Acta Biomedica Scientifica. 7(5–2):259–267. DOI 10.29413/ABS.2022-7.5-2.26
Publisher-deposited Crossref abstract and corrected DOI checked; direct page timed out. Animal physiology/model paper; does not test an actoprotector’s clinical efficacy. Useful for interpreting baseline resistance and performance as different endpoints.
Open the source trail ↗ · Publisher-listed PDF ↗Polyprenols from Siberian fir needles under adverse exposures
M. V. Melnikova; E. B. Shustov; E. A. Zolotoverkhaya; L. G. Kubarskaya; A. A. Bondarenko; A. V. Belskaya; A. A. Vataeva · 2024 · Journal Biomed. 20(3):89–93. DOI 10.33647/2074-5982-20-3-89-93
Publisher-deposited abstract and indexed original PDF citation checked. Separate preclinical natural-product branch. Authors report antioxidant, anabolic and hematopoietic effects in a combined-exposure model. Exact preparation, full controls and independent replication need appraisal; no human protective efficacy established.
Open the source trail ↗ · Publisher-listed PDF ↗Specialized athlete nutrition: evaluation of ergogenic effects
L. M. Gunina; Ye. B. Shustov; I. F. Belenichev; N. L. Vysochina; R. V. Golovashchenko; O. V. Morozova · 2022 · Pharmacia. 69(1):37–44. DOI 10.3897/pharmacia.69.e76599
Complete original PDF recovered from the institutional repository and a Pharm-SPb copy; all eight pages read, methods/results/disclosures visually checked. Methods explicitly total 127 athletes: 102 in three sports plus 25 placebo controls. Human speed claims lack raw times, arm-specific baselines and a clearly defined contrast. Animal figure values, Tables 1–2 and the mini-pig result match the 2017 report; Table 1 changes the uncertainty label from standard error to standard deviation without explaining a recalculation. Cohort independence is unresolved, so this is not counted as a new independent trial. University research programs are named as funding context; authors declare no conflict of interest.
Open the source trail ↗ · Publisher-listed PDF ↗Ergogenic sport nutrition: policy of proven effectiveness
V. N. Karkishchenko; V. S. Novikov; E. B. Shustov · 2017 · Vestnik obrazovaniya i razvitiya nauki RAEN. 21(1):15–26
Complete twelve-page original publisher PDF recovered and read; human methods, Figure 3 and animal Tables 1–2 visually checked. Printed p.22 describes a 21-man skier study at the Burnazyan center as randomized and placebo-controlled, without arm sizes or allocation details. Figure 3 gives percentages of baseline rather than raw outcomes. The same page describes a separate 2012–2013 product-appraisal program in more than 100 athletes. Animal data recur in the 2022 paper. Relationships among the 21-man study, broader appraisal and later 127-person report remain unresolved; do not add their populations as unique participants.
Open the source trail ↗ · Publisher-listed PDF ↗FDES and brain glutathione peroxidase: original method paper and corrected text
A. V. Razygraev; A. D. Yushina; I. A. Titovich · 2018 · Bulletin of Experimental Biology and Medicine. 165(2):292–295, DOI 10.1007/s10517-018-4151-5; correction/replacement text 165(4):589–592, DOI 10.1007/s10517-018-4219-2
Publication metadata and author-uploaded corrected full-text transcription checked; downloadable PDF returned 403 and was not recovered. Titovich coauthor trail; Shustov is not an author. The correction republishes the article text; an accompanying author correction list addresses wording, chemical nomenclature and a figure-axis unit. It is not a second experiment or a retraction notice. The FDES pilot reports increased brain enzyme activity under hypoxia and explicitly omits adjustment for multiple comparisons. Enzyme activity alone does not demonstrate neuronal survival or clinical neuroprotection.
Open the source trail ↗FDES neuroprotective-agent patent: the earlier provenance link
S. V. Okovityi; E. B. Shustov; V. Ts. Bolotova; I. A. Titovich · 2016 · RU2588365C1; filed 19 May 2015, published 27 June 2016
Original patent text, inventor list and dates checked. Reference 3 of the corrected 2018 enzyme paper links the named FDES candidate to this earlier university patent and the four-person research team. Patent examples and claimed mechanisms are developmental evidence; they do not establish human efficacy or independent replication of later papers.
Open the source trail ↗Pharmacological support during in-flight emergencies and landing after long space flights — acquisition target
N. N. Karkishchenko; E. B. Shustov · 2015 · XI International Scientific-Practical Conference, Manned Space Flights, 10–12 November 2015, Zvezdny Gorodok; pp.406–407
Exact title, authors and pages recovered from reference 7 of the 2017 publisher overview; original contribution not recovered. The Gagarin Cosmonaut Training Center publication list independently catalogs the 2015 XI-conference volume as 574 pages. Request pp.406–407 plus title and contents pages from that volume. A reference establishes a retrieval target, not which compounds were administered or whether a controlled flight study occurred.
Open the source trail ↗Ornithine-dependent mechanisms of muscle-fatigue correction and recovery after exercise
S. V. Okovityi; E. B. Shustov · 2020 · Voprosy kurortologii, fizioterapii i lechebnoi fizicheskoi kultury. 97(4):74–83. DOI 10.17116/kurort20209704174
Publisher review text and references checked. Review of ammonia metabolism and L-ornithine-L-aspartate, not a new clinical trial. Its reference list identifies a 2017 experimental paper by Okovityi, Radko and Krasnova; Shustov is not an author of that cited paper.
Open the source trail ↗Succinate receptors (SUCNR1) as a potential target for pharmacotherapy
S. V. Okovityi; S. V. Radko; E. B. Shustov · 2015 · Khimiko-farmatsevticheskii zhurnal. 49(9):3–7. DOI 10.30906/0023-1134-2015-49-9-3-7
Indexed publisher abstract checked; direct page retrieval timed out. Mechanistic review: succinate is discussed as a signaling ligand as well as a metabolic intermediate. Does not establish that a fumarate or succinate preparation acts through SUCNR1. The 2019 book bibliography cites different pagination (24–28); use the publisher DOI to reconcile editions.
Open the source trail ↗Ethylthiobenzimidazole fumarate under combined hypoxic and hyperthermal exposure
V. Ts. Bolotova; Yu. D. Bolotina; E. B. Shustov · 2021 · Journal Biomed. 17(3E):139–143. DOI 10.33647/2713-0428-17-3E-139-143
Indexed original publisher PDF abstract checked; direct download unavailable. Male-mouse performance study of the fumarate salt. Abstract reports activity under combined stress. Full tables, denominators and adverse findings remain to be appraised; not evidence of human benefit or equivalence to Bemitil hydrochloride.
Open the source trail ↗ · Publisher-listed PDF ↗Ethylthiobenzimidazole fumarate matrix tablets with a specified release profile
I. D. Kasymov; A. L. Marchenko; A. V. Basevich · 2025 · Regulatory Research and Medicine Evaluation. 15(5):533–540. DOI 10.30895/1991-2919-2025-763
Publisher-deposited Crossref abstract and metadata checked; publisher page returned 502. Related formulation research, not Shustov-authored. Dissolution in simulated gastrointestinal conditions, not human pharmacokinetics, tolerability or efficacy. Approximately 90% release after 12 hours is a laboratory release result, not proof of 12-hour clinical action.
Open the source trail ↗ · Publisher-listed PDF ↗The influence of peptide bioregulators on the resistance of the organism to adverse effects
A. E. Kim · 2023 · Reviews on Clinical Pharmacology and Drug Therapy. 21(2):171–177. DOI 10.17816/RCF456396
Publisher abstract and citation checked; full text restricted. Later review by a coauthor of Shustov’s 2020 peptide paper. Shustov is not an author of this review. Useful citation trail, not independent experimental replication.
Open the source trail ↗Bemitil and etomerzol during prolonged physical workload
E. B. Shustov; I. V. Aksenov; M. Yu. Bakhtin; A. A. Ikhalainen · 1994 · Antigipoksanty i aktoprotektory: itogi i perspektivy. St. Petersburg. p. 17; as cited in the 2019 book, reference 180
Original book bibliography visually checked; conference abstract not recovered. Retrieve page 17 and the proceedings title/contents pages. The later citation does not establish sample size, allocation, treatment effect or an independent cohort.
Open the source trail ↗Improving performance under physical fatigue
E. B. Shustov; A. A. Ikhalainen · 1996 · Morskoi meditsinskii zhurnal. (6):4–7; as cited in the 2019 book, reference 181
Original book bibliography visually checked; journal paper not recovered. Priority acquisition target for comparing the earlier fatigue report with the thesis and the monograph. A maritime journal title alone does not establish a shipboard population.
Open the source trail ↗Increasing human resistance to extreme exposures — two-part source lead
E. B. Shustov; A. A. Ikhalainen · 1998 · RZh Ekologiya cheloveka, separate series 86. (3):1–33; (4):1–48; book reference 182
Original book bibliography visually checked; two issues not recovered. Confirm the publication type and original title pages before treating these long entries as original studies. They may summarize work already represented in the thesis.
Open the source trail ↗FMBA guidance on preclinical antihypoxic activity and physical performance
N. N. Karkishchenko; V. N. Karkishchenko; E. B. Shustov and colleagues · 2017 · Two separate methodological recommendations: MR21-44-2017 (98 pages) and MR21.43 (133 pages), cited in the 2020 peptide paper
Publisher reference list checked; original guidance not recovered. Methodology acquisition targets, not efficacy trials. The 98-page reference is an antihypoxia methods document; it must not be relabeled as a peptide monograph.
Open the source trail ↗Bemitil ↗ · Etomerzol ↗ · Cortexin ↗ · Semax ↗ · Dalargin ↗ · Historical combinations ↗